Semarion secured £2.9 million to scale its next-generation cell assay technology and accelerate pharma adoption.
Semarion is a life sciences company that has developed the SemaCyte® platform, a microcarrier technology using materials engineering to accelerate adherent cell screening for drug discovery
Semarion is a life sciences company that has developed the SemaCyte® platform, a microcarrier technology using materials engineering to accelerate adherent cell screening for drug discovery.